Greenwood R H, Prunty F T, Silver J
Br Med J. 1973 Mar 17;1(5854):643-5. doi: 10.1136/bmj.1.5854.643.
Vitamin D deficiency is a previously unreported complication of therapy with hypnotics, and we here report a case of osteomalacia associated with long-term glutethimide administration. There was evidence of pronounced hepatic enzyme induction, and the plasma half-time of (3)H vitamin D(3) was decreased by this drug. In addition, raised levels of serum gamma-glutamyl transpeptidase, 5-nucleotidase, and leucine aminopeptidase were observed and the patient excreted large amounts of xylulose. These changes were reversed by stopping the glutethimide.
维生素D缺乏是一种以前未报道过的催眠药治疗并发症，我们在此报告一例与长期服用格鲁米特相关的骨软化症病例。有明显肝酶诱导的证据，该药物使(3)H维生素D(3)的血浆半衰期缩短。此外，观察到血清γ-谷氨酰转肽酶、5-核苷酸酶和亮氨酸氨肽酶水平升高，且患者排出大量木酮糖。停用格鲁米特后，这些变化得以逆转。
